ReleaseWire

Allergic Conjunctivitis - Pipeline Review, H1 2018; New Report Launched

DrugPipeline.net has announced the addition of “Allergic Conjunctivitis - Pipeline Review, H1 2018” research report to their website www.DrugPipeline.net

Posted: Thursday, June 07, 2018 at 9:55 AM CDT

Bangalore, India -- (SBWire) -- 06/07/2018 --Allergic Conjunctivitis - Pipeline Review, H1 2018, provides an overview of the Allergic Conjunctivitis (Ophthalmology) pipeline landscape.

Allergic conjunctivitis occurs when the clear layer of tissue lining the eyelids and covering the white of the eye (conjunctiva) become swollen or inflamed due to a reaction to pollen, dander, mold, or other allergy-causing substances. Symptoms include intense itching, puffy eyelids, widened (dilated) vessels in the clear tissue covering the white of the eye and stringy eye discharge. Treatment includes antihistamine or anti-inflammatory medication.

Report Highlights
Allergic Conjunctivitis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Allergic Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Allergic Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Allergic Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 2, 7 and 1 respectively.

Allergic Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Allergic Conjunctivitis (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Allergic Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Allergic Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Allergic Conjunctivitis (Ophthalmology)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Allergic Conjunctivitis (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Allergic Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Spanning over 78 pages "Allergic Conjunctivitis - Pipeline Review, H1 2018" report covers Introduction, Report Coverage, Allergic Conjunctivitis - Overview, Allergic Conjunctivitis - Therapeutics Development, Allergic Conjunctivitis - Therapeutics Assessment, Allergic Conjunctivitis - Companies Involved in Therapeutics Development, Allergic Conjunctivitis - Drug Profiles, Allergic Conjunctivitis - Dormant Projects, Appendix. This report Covered Companies - Accolade Pharmaceuticals LLC, Aldeyra Therapeutics Inc, AlleCures Inc, Allergan Plc, Clevexel Pharma SAS, Griffin Discoveries BV, iCo Therapeutics Inc., Ocular Therapeutix Inc, Ohr Pharmaceutical Inc, Portola Pharmaceuticals Inc, Re-Pharm Ltd, Sylentis SAU, Xencor Inc.

For more information Visit at: https://www.drugpipeline.net/global-markets-direct/allergic-conjunctivitis-pipeline-review-h1-2018

Find all Pharma and Healthcare Reports at - https://www.drugpipeline.net/catalog/pharma-healthcare

Related Reports;

Premenstrual Syndrome - Pipeline Review, H1 2018 - Visit at - https://www.drugpipeline.net/global-markets-direct/premenstrual-syndrome-pipeline-review-h1-2018

Uveal Melanoma - Pipeline Review, H1 2018 - Visit at - https://www.drugpipeline.net/global-markets-direct/uveal-melanoma-pipeline-review-h1-2018

About DrugPipeline.net
DrugPipeline.net is a market research reports distribution platform which hosts research reports from all leading global market research firms related to pharma industry. It also assist decision makers locate the right market research solution from a single place.